Why the study?
Does the perioperative continuation or withdrawal of antiplatelet therapy affect bleeding and thromboembolic risks in patients undergoing gastroenterological surgery?
Population
2012 patients undergoing gastroenterologic surgery between January 2005 and June 2010 at a single…
Comparison
Perioperative management of antiplatelet therapy. vs Patients without antiplatelet therapy.
Design
Cohort
Follow-up
postoperative period
Authors
Loading...
Caution with multidrug antiplatelet regimens and heparin bridging in gastroenterological surgery; leaves open optimal perioperative strategies pending randomized trials.
Does the perioperative continuation or withdrawal of antiplatelet therapy affect bleeding and thromboembolic risks in patients undergoing gastroenterological surgery?
Single-agent antiplatelet therapy can be safely continued in high-risk patients undergoing gastroenterologic surgery, but multidrug therapy and heparin bridging significantly increase bleeding risks.
Fujikawa et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: